SW837 Xenograft Model Service for Colon Cancer

The SW837 Xenograft Model Service for Colon Cancer provides a robust, KRAS G12C-mutant, microsatellite-stable rectal adenocarcinoma platform for preclinical drug efficacy and biomarker studies. Alfa Cytology offers fully validated SW837 xenograft construction, therapeutic monitoring, and endpoint analysis tailored to your colon cancer research programs, ensuring reproducible data from study design through final reporting.

Overview of SW837 Xenograft Model for Colon Cancer

The SW837 cell line was established from a Grade IV adenocarcinoma of the rectum in a 53-year-old Caucasian male patient. It represents a regionally specific model for colorectal cancer research, particularly valuable where anatomical and molecular distinctions between colon and rectal cancer influence therapeutic design. The line exhibits epithelial morphology with brush borders, produces carcinoembryonic antigen (CEA), and expresses keratin, confirming its intestinal epithelial lineage. Genetically, SW837 harbors a KRAS G12C mutation and a TP53 mutation (C to T in codon 248, Arg to Trp substitution), placing it within the inflammatory molecular subtype of colorectal cancer. It is microsatellite stable (MSS) and negative for CSAp and colon antigen 3 expression. These molecular features drive constitutive MAPK pathway activation and resistance to EGFR-targeted therapies, mirroring clinical outcomes in KRAS-mutant rectal tumors.

In vivo, SW837 xenografts display moderately differentiated adenocarcinoma morphology with glandular formation, occasional mucin production, and focal central necrosis. Tumor cells show columnar architecture with basally located nuclei and eosinophilic cytoplasm. Immunohistochemical profiling reveals strong membranous E-cadherin, moderate beta-catenin expression with partial cytoplasmic localization indicative of active Wnt signaling, and positivity for CK20 and CEA. The model demonstrates consistent engraftment in immunodeficient mice with predictable growth kinetics, making it suitable for multi-cycle therapeutic studies, radiation combination experiments, and investigations of next-generation KRAS G12C inhibitors, antibody-drug conjugates, and synthetic lethality strategies.

Figure 1. AB-8263 dose-dependently suppressed colorectal cancer cell proliferation and colony formation in vitro. (Liu, Xin-Mo, et al., 2023)

Cell Line Information: SW837

The SW837 cell line is a well-characterized human rectal adenocarcinoma line with the following detailed profile:

Our Services

Alfa Cytology provides comprehensive SW837 xenograft model services encompassing cell line authentication, in vivo model construction, therapeutic intervention design, and multi-parameter endpoint analysis. Our preclinical platform is optimized for colon cancer drug development programs, delivering reproducible tumor growth data, pharmacokinetic insights, and histopathological evaluations to accelerate your candidate selection process.

Workflow of SW837 Xenograft Model Construction

The construction of SW837 xenograft models at Alfa Cytology follows a standardized, quality-controlled workflow designed to ensure high engraftment rates, consistent tumor growth kinetics, and reliable therapeutic readouts. Each project is initiated with a detailed study design consultation to align model parameters with specific research objectives.

1. Cell Line Authentication and Quality Control: SW837 cells are authenticated by short-tandem repeat (STR) profiling and confirmed for KRAS G12C and TP53 mutation status. Mycoplasma testing and viability assessment are performed prior to inoculation to ensure culture purity and optimal cell health.
2. Cell Preparation and Inoculum Standardization: Exponentially growing SW837 cells are harvested, washed, and resuspended in a serum-free medium mixed with Matrigel at a defined ratio. Cell concentration is adjusted to 1 x 10^6 cells per 100-200 microL inoculum for subcutaneous delivery.
3. Animal Preparation and Subcutaneous Inoculation: Immunodeficient mice (athymic nude or NOD/SCID, 6-8 weeks old) are acclimatized and randomized. SW837 cells are injected subcutaneously into the right flank using aseptic technique. Tumor engraftment is typically detectable within 8-12 days.
4. Tumor Monitoring and Randomization: Tumor dimensions are measured twice weekly via caliper in three perpendicular axes. Mice are randomized into treatment cohorts when average tumor volumes reach 100-150 mm^3, ensuring balanced baseline tumor burden across groups.
5. Therapeutic Intervention and Dosing: Test compounds are administered according to predefined dosing schedules (route, frequency, and duration). Vehicle controls and reference standards are included. Body weight and clinical signs are monitored throughout the study period.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tissue samples are fixed in formalin for histopathology (H&E, IHC for Ki-67, CK20, CEA, p53) or snap-frozen for molecular analysis. Blood is collected for pharmacokinetic profiling if required.

Figure 2: Schematic workflow illustrating the derivation and construction of the SW837 Xenograft Model at Alfa Cytology.

Case Study-SW837 Xenograft Model Development

In a representative preclinical study, SW837 xenografts were established to evaluate the efficacy of a novel targeted therapeutic agent in KRAS G12C-mutant colorectal cancer. Following successful engraftment and randomization at 100-150 mm^3, mice received multi-cycle treatment with the investigational compound or vehicle control. The study demonstrated dose-dependent tumor growth inhibition, with treated cohorts showing significant reductions in tumor volume compared to controls. Histopathological analysis revealed decreased Ki-67 proliferation indices and increased apoptotic markers in responder tumors, while pharmacokinetic profiling confirmed adequate systemic exposure. These data support the utility of the SW837 model for translational drug development, with full datasets available upon request for client-specific program design.

Why Choose Alfa Cytology?

Alfa Cytology delivers scientifically rigorous, operationally efficient SW837 xenograft model services that advance colon cancer preclinical research from candidate validation to IND-enabling decision points.

• Validated Cell Lines: All SW837 stocks are STR-authenticated and mutation-verified for KRAS G12C and TP53 status, ensuring genetic fidelity throughout your study.
• Standardized Workflows: Our SOP-driven model construction, dosing, and endpoint protocols minimize inter-study variability and support cross-program data comparability.
• Comprehensive Endpoints: We offer tumor growth kinetics, body weight monitoring, histopathology (H&E, IHC), biomarker analysis, and pharmacokinetic sampling within a single service package.
• Flexible Study Design: Customizable dosing schedules, combination regimens, and radiation sensitization protocols are available to match your specific mechanistic or translational objectives.
• Regulatory-Ready Documentation: Detailed study reports, raw data files, and quality control records are provided to support internal decision-making and regulatory submissions.
• Dedicated Project Management: Each client is assigned a scientific project manager to ensure transparent communication, timeline adherence, and rapid issue resolution.

Contact Us

To discuss your SW837 xenograft model requirements or request a customized study proposal, please contact us today. Our preclinical oncology team is ready to design a study program that aligns with your colon cancer drug development timeline and delivers the high-quality data you need to advance your pipeline. You can also reach out to us via email or through our online inquiry form for a prompt, confidential response.

For research use only. Not intended for any clinical use.